Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Over the last 12 months, insiders at Kala Pharmaceuticals, Inc. have bought $0 and sold $159,016 worth of Kala Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Kala Pharmaceuticals, Inc. have bought $120.06M and sold $698,693 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 80 shares for transaction amount of $304 was made by Bazemore Todd (Chief Operating Officer) on 2020‑10‑22.
2024-05-31 | Sale | Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 7,392 0.2379% | $6.09 | $45,017 | -9.60% | |
2024-05-31 | Sale | Brazzell Romulus K | SEE REMARKS | 2,002 0.0644% | $6.09 | $12,192 | -9.60% | |
2024-05-31 | Sale | Bazemore Todd | SEE REMARKS | 2,093 0.0673% | $6.09 | $12,746 | -9.60% | |
2024-05-31 | Sale | Kharabi Darius | CHIEF BUSINESS OFFICER | 231 0.0074% | $6.09 | $1,407 | -9.60% | |
2024-05-31 | Sale | Reumuth Mary | CHIEF FINANCIAL OFFICER | 1,786 0.0575% | $6.09 | $10,877 | -9.60% | |
2024-01-04 | Sale | Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 4,539 0.1618% | $6.73 | $30,547 | +0.79% | |
2024-01-04 | Sale | Brazzell Romulus K | SEE REMARKS | 1,617 0.0577% | $6.74 | $10,899 | +0.79% | |
2024-01-04 | Sale | Trachtenberg Eric | SEE REMARKS | 1,227 0.0438% | $6.74 | $8,270 | +0.79% | |
2024-01-04 | Sale | Reumuth Mary | CHIEF FINANCIAL OFFICER | 1,227 0.0438% | $6.74 | $8,270 | +0.79% | |
2024-01-04 | Sale | Kharabi Darius | CHIEF BUSINESS OFFICER | 1,385 0.0494% | $6.73 | $9,321 | +0.79% | |
2024-01-04 | Sale | Bazemore Todd | SEE REMARKS | 1,405 0.0502% | $6.74 | $9,470 | +0.79% | |
2023-01-04 | Sale | Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 198 0.0065% | $28.54 | $5,651 | -66.29% | |
2023-01-04 | Sale | Brazzell Romulus K | SEE REMARKS | 73 0.0024% | $28.53 | $2,083 | -66.29% | |
2023-01-04 | Sale | Bazemore Todd | SEE REMARKS | 62 0.002% | $28.54 | $1,769 | -66.29% | |
2023-01-04 | Sale | Reumuth Mary | CHIEF FINANCIAL OFFICER | 60 0.002% | $28.54 | $1,712 | -66.29% | |
2023-01-04 | Sale | Trachtenberg Eric | SEE REMARKS | 60 0.002% | $28.55 | $1,713 | -66.29% | |
2022-10-26 | Sale | Brazzell Romulus K | SEE REMARKS | 261 0.0168% | $6.51 | $1,699 | +128.67% | |
2022-10-26 | Sale | Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 561 0.0363% | $6.52 | $3,658 | +128.67% | |
2022-10-26 | Sale | Reumuth Mary | CHIEF FINANCIAL OFFICER | 194 0.0125% | $6.51 | $1,263 | +128.67% | |
2022-10-26 | Sale | Bazemore Todd | SEE REMARKS | 214 0.0138% | $6.51 | $1,393 | +128.67% |
Iwicki Mark T | CHIEF EXECUTIVE OFFICER | 278923 10.6313% | $4.60 | 0 | 8 | |
Brazzell Romulus K | SEE REMARKS | 89471 3.3965% | $4.60 | 0 | 8 | |
Trachtenberg Eric | SEE REMARKS | 68066 2.5274% | $4.60 | 0 | 7 | |
Reumuth Mary | CHIEF FINANCIAL OFFICER | 64350 2.4557% | $4.60 | 0 | 8 | |
Kharabi Darius | CHIEF BUSINESS OFFICER | 64886 2.4179% | $4.60 | 0 | 2 | |
Bazemore Todd | SEE REMARKS | 87693 0% | $4.60 | 3 | 8 | <0.0001% |
RA CAPITAL MANAGEMENT, L.P. | 10874613 403.7924% | $4.60 | 3 | 0 | <0.0001% | |
Shah Rajeev M. | 7039613 261.3925% | $4.60 | 3 | 2 | <0.0001% | |
ORBIMED ADVISORS LLC | 10 percent owner | 3447840 128.024% | $4.60 | 14 | 0 | <0.0001% |
Grunberg Gregory | director | 2534854 94.1233% | $4.60 | 3 | 0 | <0.0001% |
Longitude Capital Partners II, LLC | 10 percent owner | 2270946 84.324% | $4.60 | 1 | 0 | <0.0001% |
CDK ASSOCIATES, L.L.C. | 10 percent owner | 763755 28.3595% | $4.60 | 1 | 0 | <0.0001% |
Chen Hongming | CHIEF SCIENTIFIC OFFICER | 204515 7.594% | $4.60 | 0 | 4 | |
Rosen Howard B | director | 8240 0.306% | $4.60 | 1 | 0 | +3.16% |
Baker Bros Advisors LP | $2.12M | 9.47 | 266,613 | 0% | +$0 | 0.03 | |
Millennium Management LLC | $1.05M | 4.74 | 133,403 | +0.55% | +$5,715.36 | <0.01 | |
Ubs Oconnor Llc | $568,823.00 | 2.58 | 72,554 | New | +$568,823.00 | 0.05 | |
The Vanguard Group | $334,589.00 | 1.49 | 41,981 | +49.74% | +$111,149.76 | <0.0001 | |
BlackRock | $216,601.00 | 0.97 | 27,177 | -0.53% | -$1,147.68 | <0.0001 | |
Board Of Trustees Of The Leland Stanford Junior University | $168,382.00 | 0.75 | 21,127 | 0% | +$0 | 0.02 | |
Geode Capital Management | $142,369.00 | 0.65 | 18,153 | -1.69% | -$2,446.93 | <0.0001 | |
Citadel Advisors LLC | $105,589.00 | 0.48 | 13,468 | New | +$105,589.00 | <0.0001 | |
Renaissance Technologies | $91,000.00 | 0.41 | 11,400 | -19.15% | -$21,552.63 | <0.0001 | |
Knights of Columbus Asset Advisors LLC | $19,263.00 | 0.09 | 2,417 | -50% | -$19,263.00 | <0.01 | |
UBS | $17,335.00 | 0.08 | 2,175 | +212.5% | +$11,787.80 | <0.0001 | |
Tower Research Capital | $12,919.00 | 0.06 | 1,621 | -62.8% | -$21,805.29 | <0.0001 | |
Morgan Stanley | $10,847.00 | 0.05 | 1,361 | -16.04% | -$2,072.17 | <0.0001 | |
Covestor Ltd | $8,000.00 | 0.04 | 1,048 | -16.96% | -$1,633.59 | 0.01 | |
Banque Cantonale Vaudoise | $6,000.00 | 0.03 | 808 | 0% | +$0 | <0.0001 | |
Compagnie Lombard Odier Scma | $3,136.00 | 0.01 | 400 | 0% | +$0 | <0.0001 | |
Citigroup | $2,321.00 | 0.01 | 296 | 0% | +$0 | <0.0001 | |
Advisor Group Holdings Inc | $1,920.00 | 0.01 | 241 | 0% | +$0 | <0.0001 | |
CWM LLC | $2,000.00 | 0.01 | 200 | 0% | +$0 | <0.0001 | |
Steward Partners Investment Advisory LLC | $956.00 | <0.01 | 120 | 0% | +$0 | <0.0001 | |
Bank of America | $885.00 | <0.01 | 111 | -95.71% | -$19,741.08 | <0.0001 | |
Wells Fargo | $143.00 | <0.01 | 18 | +5.88% | +$7.94 | <0.0001 | |
Old Point Trust & Financial Service | $159.00 | <0.01 | 20 | New | +$159.00 | <0.0001 | |
PNC Financial Services | $159.00 | <0.01 | 20 | New | +$159.00 | <0.0001 | |
JPMorgan Chase | $274.00 | <0.01 | 35 | +12.9% | +$31.31 | <0.0001 | |
Royal Bank of Canada | $0 | <0.01 | 23 | -63.49% | -$0 | <0.0001 | |
Group One Trading | $24.00 | <0.01 | 3 | 0% | +$0 | <0.0001 | |
Parallel Advisors, LLC | $8.00 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
Qube Research & Technologies | $24.00 | <0.01 | 3 | 0% | +$0 | <0.0001 |